Cortex Therapeutics develops treatments that target the fundamental biological mechanisms governing neuronal survival, aiming to intervene in neurodegeneration at its core. By focusing on shared pathways that underlie multiple neurodegenerative diseases, the company seeks to create therapies that can restore neuron function across a range of conditions, rather than addressing each disease’s unique differences.
Funding
Funding not disclosed
Founders
Product
Problem
Neurodegenerative diseases such as Alzheimer’s, Parkinson’s and ALS progressively destroy neurons, and current drug development programs focus on disease‑specific targets, resulting in few therapies that can modify disease progression.
Solution
Cortexatherapeutics is creating disease‑modifying treatments that act on the core biological mechanisms governing neuronal survival. By targeting pathways that are common to multiple neurodegenerative conditions, the company aims to restore the cellular processes required for neuron health regardless of the specific disease. Their platform combines multi‑omics discovery, high‑throughput screening, and translational models to identify and validate compounds that reactivate these survival mechanisms. The resulting therapeutics are intended to be evaluated across Alzheimer’s, Parkinson’s, ALS, and potentially other disorders, streamlining development and increasing the chance of clinical benefit. Preclinical data feed into biomarker strategies that monitor target engagement and neuronal function in early‑phase trials. This unified approach seeks to reduce development timelines while delivering meaningful outcomes for patients.
Target Audience
Primary customers are pharmaceutical and biotechnology companies, as well as clinical research organizations, seeking disease‑modifying candidates that can be applied across Alzheimer’s, Parkinson’s, ALS, and related neurodegenerative disorders.
Features
- Systematic identification of neuronal survival pathways shared across major neurodegenerative diseases using multi‑omics and functional genomics
- High‑throughput screening of small molecules and biologics for ability to restore identified survival mechanisms in disease‑relevant cellular models
- Integrated translational pipeline linking in vitro hits to animal models that recapitulate common neurodegenerative pathology
- Biomarker development program to measure target engagement and neuronal health signals in patients
- Flexible drug candidate portfolio designed for evaluation in multiple indications under a single regulatory strategy
- Proprietary data analytics framework that prioritizes candidates based on cross‑disease efficacy and safety profiles